Johns Hopkins University and the Medicines Patient Pool (MPP) have signed a license agreement to facilitate the clinical development of the tuberculosis drug, sutezolid. Sutezolid, an oxazolidinone antibiotic in the same class as linezolid, has shown promise in use as a compound in early stage trials to be more potent and less toxic in the treatment of TB.
The CDC has recently published Modules 6 and 8 of the Self-Study Modules in Spanish. These Self-Study Modules on Tuberculosis are a series of educational modules designed to provide information about TB in a self-study format. The series consists of a total of nine modules that are separated into two courses. The first course, Modules 1-5, provides basic information on TB. The second course, Modules 6-9, provides more specific TB programmatic information.
Jointly sponsored by the Regional Training and Medical Consultation Centers, the course "Optimizing Outcomes of Drug-Resistant Tuberculosis in High-Resource, Low-Incidence Settings" will be offered as part of The Union-NAR End TB 2017 Conference in Vancouver, Canada.
This 3-hour training will provide an overview of the medical management and case management of drug-resistant tuberculosis including a discussion of diagnostics, treatment options, special situations, and a panel discussion with clinical and programmatic perspectives on the use of the short course MDR regimen in high-resource, low-incidence settings.
Location: Sheraton Vancouver Wall Centre
Date: February 22
Time: 12:00 p.m. - 3:00 p.m.